Skip to main content
Clinical Trials/NCT04143568
NCT04143568
Completed
Not Applicable

Analysis of Circulating Progenitor Cells Levels in Periodontal Disease Patients

University of Messina1 site in 1 country167 target enrollmentFebruary 1, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Metabolic Disease
Sponsor
University of Messina
Enrollment
167
Locations
1
Primary Endpoint
Evaluation of endothelial progenitor cells level
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Recently, a key role played in the ethiology of periodontitis has been highlighted by a subtype of stem cells derived from bone marrow, the circulating endothelial progenitor cells (EPCs). EPCs possess the ability to express surface antigens of endothelial and hematopoietic stem cells and to assist in maintaining vascular integrity and the repair mechanism of the endothelium. Among the main markers for the analysis of EPCs levels are CD34+, CD133+ and the kinase insert domain-containing receptor (KDR). CD34+ and CD133+ originate from hematopoietic stem cell antigens whereas KDR is a specific marker of endothelial cells. More specifically, CD34+ and CD133+/ KDR+ allows less mature and mature EPCs to be evaluated.

Detailed Description

The aim of the present study was to investigate the association between endothelial progenitor cells (EPCs) levels subtype (CD133+/KDR+), in patients with periodontitis. Furthermore, the objective was to determine if the periodontal status influenced CD133+/KDR+ levels.

Registry
clinicaltrials.gov
Start Date
February 1, 2016
End Date
November 30, 2018
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gaetano Isola, DDS, PhD

Junior Assistant Professor

University of Messina

Eligibility Criteria

Inclusion Criteria

  • Presence of at least 16 teeth
  • CP with a minimum of 40% of sites with a clinical attachment level (CAL)
  • ≥2mm and probing depth (PD) ≥4mm;
  • Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs
  • Presence of ≥40% sites with bleeding on probing (BOP)

Exclusion Criteria

  • Intake of contraceptives
  • Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study
  • Status of pregnancy or lactation
  • Previous history of excessive drinking
  • Allergy to local anaesthetic
  • Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.

Outcomes

Primary Outcomes

Evaluation of endothelial progenitor cells level

Time Frame: 1 year

Changes of endothelial progenitor cells level

Study Sites (1)

Loading locations...

Similar Trials